Targeting Trop-2 as a Cancer Driver

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01. June 16, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01207 Journal of Clinical Oncology - published online before print August 7, 2023 PMID: 37549340 Targeting Trop-2 as a Cancer Driver Emanuela Guerra , PhD1,2xEmanuela GuerraSearch for articles by this author; Marco Trerotola , PhD1,2xMarco TrerotolaSearch for articles by this author; and Saverio Alberti , MD, PhD3xSaverio AlbertiSearch for articles by this author Show More 1Laboratory of Cancer Pathology, Center for Advanced Studies and Technology (CAST), G. d'Annunzio University of Chieti-Pescara, Chieti, Italy2Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy3Unit of Medical Genetics, Department of Biomedical Sciences—BIOMORF, University of Messina, Messina, Italy https://doi.org/10.1200/JCO.23.01207 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: Emanuela Guerra, Saverio AlbertiManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTTargeting Trop-2 as a Cancer DriverThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Emanuela GuerraStock and Other Ownership Interests: Mediterranea Theranostic SrlResearch Funding: Mediterranea Theranostic SrlPatents, Royalties, Other Intellectual Property: Inventor in patents WO2016087651 and WO2017084763,Saverio AlbertiLeadership: Oncoxx BiotechStock and Other Ownership Interests: Oncoxx BiotechResearch Funding: Oncoxx BiotechPatents, Royalties, Other Intellectual Property: novel anti-cancer drugs and companion diagnosticsTravel, Accommodations, Expenses: Oncoxx BiotechNo other potential conflicts of interest were reported. Companion First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01